Speakers present the common and distinct pathways involved in hepatic stellate cell activation and fibrogenesis in metabolic dysfunction-associated steatohepatitis (MASH) and MetALD in relation to disease-specific therapeutic approaches.
Explain what is known about the common and distinct pathways contributing to fibrogenesis in MASH versus MetALD.
Describe how knowledge about the common and distinct pathways contributing to fibrogenesis in MASH and MetALD may aid in the design of disease-specific therapeutic interventions.